Biotech Values

[daved]

I bought MCU this morning, drbio,dunno and crs

The P3 trial for MC1 will be very short compared to most and it looks like an 85%+ probability. The P2 trial was big and nothing changes for the P3.

I like the fact that the recent dilution was oversold.

I expect Merck to pick up the option to market the Aggrostat/MC1 combo but it's not neccessary.

The diabetes indication addresses a large market.

I get ongoing revenue, 45 mil in cash and lots of irons in the fire for my fully diluted (at 1.7/sh) 158 mil cap.

Dave